1343 related articles for article (PubMed ID: 22263674)
1. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
[TBL] [Abstract][Full Text] [Related]
3. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
Ballantyne CM; Davidson MH; Setze CM; Kelly MT
J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
10. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
11. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
13. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
15. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Kipnes MS; Roth EM; Rhyne JM; Setze CM; Lele A; Kelly MT; Sleep DJ; Stolzenbach JC
Clin Drug Investig; 2010; 30(1):51-61. PubMed ID: 19995098
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
18. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Ballantyne CM; Jones PH; Kelly MT; Setze CM; Lele A; Thakker KM; Stolzenbach JC
Cardiovasc Drugs Ther; 2011 Feb; 25(1):59-67. PubMed ID: 21416219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]